Vical and Mycoses Study Group Education and Research Consortium Establish Collaboration to Advance Vical’s Novel Antifungal

Medical Device Investing

Vical (Nasdaq:VICL) and the Mycoses Study Group Education and Research Consortium announced the establishment of a collaboration to advance Vical’s novel antifungal drug product candidate for the treatment of invasive aspergillosis. As quoted in the press release: “We are excited to establish this collaboration with the world’s leading mycology clinicians and thought leaders,” said Dr. …

As quoted in the press release:

“We are excited to establish this collaboration with the world’s leading mycology clinicians and thought leaders,” said Dr. Mammen “Anza” Mammen, Vical’s Senior Vice President, Clinical Development. “We believe the MSGERC will add substantial value to our VL-2397 antifungal program by serving as advisors to our Phase 2 trial and helping provide exposure for the study among their member clinicians who may be interested in taking part as investigators.”

Click here to read the full press release.

phase 2 trial product candidate vical Medical Device Investing